TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Neurogene ( (NGNE) ) is now available.
On November 12, 2025, Neurogene Inc. announced positive interim clinical data from its Phase 1/2 trial of NGN-401 gene therapy for females with Rett syndrome, showing significant functional gains in pediatric participants. The results indicate durable improvements across multiple domains, suggesting NGN-401’s potential as a best-in-class gene therapy, with no severe adverse events reported, enhancing Neurogene’s position in the gene therapy market for neurological disorders.
The most recent analyst rating on (NGNE) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Neurogene stock, see the NGNE Stock Forecast page.
Spark’s Take on NGNE Stock
According to Spark, TipRanks’ AI Analyst, NGNE is a Underperform.
Neurogene’s overall score is primarily influenced by its financial performance, which is challenged by zero revenues and significant net losses. While the stock shows some technical strength, the high beta and potential overbought conditions pose risks. The valuation reflects the speculative nature of investing in an early-stage biotech firm.
To see Spark’s full report on NGNE stock, click here.
More about Neurogene
Neurogene Inc. is a clinical-stage company focused on developing genetic medicines for rare neurological diseases. The company is advancing novel gene therapy approaches to address central nervous system disorders, aiming to maximize efficacy and safety through innovative delivery methods and proprietary technology.
Average Trading Volume: 202,092
Technical Sentiment Signal: Buy
Current Market Cap: $403.9M
See more data about NGNE stock on TipRanks’ Stock Analysis page.